Abstract
This study evaluated efficacy and safety of darbepoetin alfa administered every 3 weeks (Q3W) at fixed doses of 300 or 500 lg with or without intravenous (IV) iron in treating anemia in patients receiving multi-cycle chemotherapy. This Phase 2, double-blind, 2 × 2 factorial study randomized patients to one of four treatment arms; darbepoetin alfa 300 μg (n = 62), darbepoetin alfa 300 μg plus IV iron (n = 60), darbepoetin alfa 500 μg (n = 60), or darbepoetin alfa 500 μg plus IV iron (n = 60). Patients had nonmyeloid malignancies, hemoglobin levels ≤10 g dL-1, and no iron deficiency. Primary endpoint was achievement of target hemoglobin (≥11 g dL-1). Secondary endpoints included incidence of transfusions and change in Functional Assessment of Cancer Therapy Fatigue (FACT-F) score from baseline to end of study. Safety was evaluated by incidence of adverse events. No evidence of a statistically significant interaction between darbepoetin alfa dose received and IV iron usage was observed, therefore, results are provided separately comparing darbepoetin alfa doses and comparing IV iron usage groups. Similar proportions of patients receiving darbepoetin alfa 300 or 500 μg achieved target hemoglobin (75 and 78%, respectively); Kaplan-Meier median time to target hemoglobin was 10 and 8 weeks, respectively. More patients receiving IV iron (82%) than not receiving IV iron (72%) achieved hemoglobin target. Adverse events profiles were similar for darbepoetin alfa treatment groups. Transient anaphylactoid reactions were reported in two patients receiving IV iron. Darbepoetin alfa at 300 μg Q3W and 500 μg Q3W showed similar benefit, while added IV iron improved treatment response in these patients.
| Original language | English |
|---|---|
| Pages (from-to) | 655-663 |
| Number of pages | 9 |
| Journal | American Journal of Hematology |
| Volume | 85 |
| Issue number | 9 |
| DOIs | |
| State | Published - 2010 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Hematology
- Medicine(all)
Cite this
Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. / Auerbach, Michael; Silberstein, Peter T.; Webb, R. Timothy; Averyanova, Svetlana; Ciuleanu, Tudor Eliade; Shao, James; Bridges, Kenneth.
In: American Journal of Hematology, Vol. 85, No. 9, 2010, p. 655-663.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia
AU - Auerbach, Michael
AU - Silberstein, Peter T.
AU - Webb, R. Timothy
AU - Averyanova, Svetlana
AU - Ciuleanu, Tudor Eliade
AU - Shao, James
AU - Bridges, Kenneth
PY - 2010
Y1 - 2010
N2 - This study evaluated efficacy and safety of darbepoetin alfa administered every 3 weeks (Q3W) at fixed doses of 300 or 500 lg with or without intravenous (IV) iron in treating anemia in patients receiving multi-cycle chemotherapy. This Phase 2, double-blind, 2 × 2 factorial study randomized patients to one of four treatment arms; darbepoetin alfa 300 μg (n = 62), darbepoetin alfa 300 μg plus IV iron (n = 60), darbepoetin alfa 500 μg (n = 60), or darbepoetin alfa 500 μg plus IV iron (n = 60). Patients had nonmyeloid malignancies, hemoglobin levels ≤10 g dL-1, and no iron deficiency. Primary endpoint was achievement of target hemoglobin (≥11 g dL-1). Secondary endpoints included incidence of transfusions and change in Functional Assessment of Cancer Therapy Fatigue (FACT-F) score from baseline to end of study. Safety was evaluated by incidence of adverse events. No evidence of a statistically significant interaction between darbepoetin alfa dose received and IV iron usage was observed, therefore, results are provided separately comparing darbepoetin alfa doses and comparing IV iron usage groups. Similar proportions of patients receiving darbepoetin alfa 300 or 500 μg achieved target hemoglobin (75 and 78%, respectively); Kaplan-Meier median time to target hemoglobin was 10 and 8 weeks, respectively. More patients receiving IV iron (82%) than not receiving IV iron (72%) achieved hemoglobin target. Adverse events profiles were similar for darbepoetin alfa treatment groups. Transient anaphylactoid reactions were reported in two patients receiving IV iron. Darbepoetin alfa at 300 μg Q3W and 500 μg Q3W showed similar benefit, while added IV iron improved treatment response in these patients.
AB - This study evaluated efficacy and safety of darbepoetin alfa administered every 3 weeks (Q3W) at fixed doses of 300 or 500 lg with or without intravenous (IV) iron in treating anemia in patients receiving multi-cycle chemotherapy. This Phase 2, double-blind, 2 × 2 factorial study randomized patients to one of four treatment arms; darbepoetin alfa 300 μg (n = 62), darbepoetin alfa 300 μg plus IV iron (n = 60), darbepoetin alfa 500 μg (n = 60), or darbepoetin alfa 500 μg plus IV iron (n = 60). Patients had nonmyeloid malignancies, hemoglobin levels ≤10 g dL-1, and no iron deficiency. Primary endpoint was achievement of target hemoglobin (≥11 g dL-1). Secondary endpoints included incidence of transfusions and change in Functional Assessment of Cancer Therapy Fatigue (FACT-F) score from baseline to end of study. Safety was evaluated by incidence of adverse events. No evidence of a statistically significant interaction between darbepoetin alfa dose received and IV iron usage was observed, therefore, results are provided separately comparing darbepoetin alfa doses and comparing IV iron usage groups. Similar proportions of patients receiving darbepoetin alfa 300 or 500 μg achieved target hemoglobin (75 and 78%, respectively); Kaplan-Meier median time to target hemoglobin was 10 and 8 weeks, respectively. More patients receiving IV iron (82%) than not receiving IV iron (72%) achieved hemoglobin target. Adverse events profiles were similar for darbepoetin alfa treatment groups. Transient anaphylactoid reactions were reported in two patients receiving IV iron. Darbepoetin alfa at 300 μg Q3W and 500 μg Q3W showed similar benefit, while added IV iron improved treatment response in these patients.
UR - http://www.scopus.com/inward/record.url?scp=77956453903&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77956453903&partnerID=8YFLogxK
U2 - 10.1002/ajh.21779
DO - 10.1002/ajh.21779
M3 - Article
C2 - 20661916
AN - SCOPUS:77956453903
VL - 85
SP - 655
EP - 663
JO - American Journal of Hematology
JF - American Journal of Hematology
SN - 0361-8609
IS - 9
ER -